UBS AM’s Kyverna Therapeutics KYTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.25K Buy
+625
New +$4.93K ﹤0.01% 3936
2024
Q4
– Sell
-101,900
Closed -$498K – 2770
2024
Q3
$498K Sell
101,900
-13,465
-12% -$104K ﹤0.01% 2647
2024
Q2
$865K Buy
115,365
+9,465
+9% +$145K ﹤0.01% 2449
2024
Q1
$2.63M Buy
+105,900
New +$2.95M ﹤0.01% 1541

Other funds holding KYTX

UBS AM's KYTX Position: Q3 2026 in Review

UBS AM opened a new position in Kyverna Therapeutics (KYTX) in Q3 2026: 625 shares worth $4.25K. The stake represents ﹤0.01% of the portfolio and ranks #3936 among its holdings. This is a return to the name: UBS AM previously reported a position in KYTX as recently as Q3 2024.

UBS AM first reported a position in KYTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $2.63M in Q1 2024. 106 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • UBS AM held 625 shares of Kyverna Therapeutics worth $4.25K as of Q3 2026.
  • Kyverna Therapeutics was a new UBS AM position in Q3 2026.
  • Kyverna Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #3936 holding.
  • UBS AM first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • UBS AM's Kyverna Therapeutics position peaked at $2.63M in Q1 2024.
  • 106 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.